share_log

Truist Securities Maintains Buy on Autolus Therapeutics, Raises Price Target to $11

Moomoo 24/7 ·  Apr 9 13:41

Truist Securities analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from $10 to $11.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment